Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
2025 August
  • Home
  • Archive for August, 2025
Global Trial Podcast
user

Host: Julio Martinez linkedin-img

user

Guest: Ross Youngs linkedin-img


×

Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere

  • August 29 2025
  • Video - Date: 08/28/2025
  • Length: 29.44 min

Summary –

Discussed in this Podcast

→ How microbiome mining could cure cancer, Alzheimer’s & more
→ Processing 2 MILLION liters of water daily to extract microbes
→ Accessing drug-like molecules that evolution perfected over 3.4 billion years
→ Why this could be worth TRILLIONS in the next 25 years
→ Transforming agriculture, cosmetics & environmental remediation

lightbulbKEY TAKEAWAY: “Microbes have always been chemical researchers and factories of life. Biosortia’s breakthrough technology now effectively opens the door to ALL microbes.” – Ross Youngs

This technology could literally transform how we discover new medicines and accelerate first-in human trials globally!

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI

  • August 15 2025

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI (August 15, 2025) by Mariam E Sunny. Summary Superluminal to receive payments, equity investment, royalties Lilly, Novo pursuing GPCR-targeting drugs for obesity Superluminal’s lead candidate not part of deal with Lilly. Aug 14 (Reuters) – Eli Lilly (LLY.N), has signed a deal worth $1.3 billion with privately

Continue Reading

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity

  • August 14 2025

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity Collaboration focused on undisclosed GPCR targets Company to receive an upfront and near-term payments, including an equity investment, as well as additional development and commercial milestones, and tiered royalties (August 14, 2025) by Sarah Sutton. Boston, MA — August 14, 2025

Continue Reading

RSS Industry News

  • Gut microbiome profiling of a migratory Anser serrirostris population reveals two groups with distinct pathogen and ARG contents December 20 2025
  • Oral short-chain fatty acid-producing bacteria may be associated with biological age and cognition among the oldest old December 20 2025
  • Distinct gastrointestinal microbial signatures predict parasite levels in controlled Plasmodium infections in both rhesus macaques and humans December 19 2025
  • Genetic architecture and mechanisms of host-microbiome interactions from a multi-cohort analysis of outbred laboratory rats December 18 2025
  • Biological and technical variability in mouse microbiota analysis and implications for sample size determination December 18 2025
  • Gut microbiota modulates aversive learning and memory of honeybees (Apis mellifera) December 18 2025
  • Pollutants disrupt gut microbiota December 15 2025
  • Neonicotinoid-induced signature dysbiosis identified via metagenomic sequencing of the honey bee gut microbiome December 13 2025
  • Gut microbiome predicts personalized responses to dietary fiber in prediabetes: a randomized, open-label trial December 13 2025
  • Short-chain fatty acids mediate interactions between immune responses and commensal bacteria in high altitude yaks December 13 2025
Quick Link
  • Products & Services
  • Blog
  • Contact
Recent Posts
  • Evolution, Purpose, and the Leaders We Need Now, with Ross
  • Mining the Microbiome: Unlocking Hidden Chemistry at Scale-Driven Polypharmacology Drug Discovery by Monetizing Innovation
  • Microbiome Metabolic Fingerprinting: The Critical Control Layer for Deep Space Survival and Terrestrial Health (D2)
Sign up for our newsletter
Loading
Biosortia Microbiomics © 2024. All Rights Reserved